CN120114438A - 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法 - Google Patents

施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法 Download PDF

Info

Publication number
CN120114438A
CN120114438A CN202411012641.9A CN202411012641A CN120114438A CN 120114438 A CN120114438 A CN 120114438A CN 202411012641 A CN202411012641 A CN 202411012641A CN 120114438 A CN120114438 A CN 120114438A
Authority
CN
China
Prior art keywords
rtx
hypertension
administration
population
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411012641.9A
Other languages
English (en)
Chinese (zh)
Inventor
欧文·H·朱克
王汉军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska System
Original Assignee
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska System filed Critical University of Nebraska System
Publication of CN120114438A publication Critical patent/CN120114438A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411012641.9A 2016-04-13 2017-04-13 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法 Pending CN120114438A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
US62/322,079 2016-04-13
CN201780036933.8A CN109562096A (zh) 2016-04-13 2017-04-13 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780036933.8A Division CN109562096A (zh) 2016-04-13 2017-04-13 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法

Publications (1)

Publication Number Publication Date
CN120114438A true CN120114438A (zh) 2025-06-10

Family

ID=60039929

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411012641.9A Pending CN120114438A (zh) 2016-04-13 2017-04-13 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法
CN201780036933.8A Pending CN109562096A (zh) 2016-04-13 2017-04-13 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780036933.8A Pending CN109562096A (zh) 2016-04-13 2017-04-13 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法

Country Status (9)

Country Link
US (3) US20170296506A1 (https=)
EP (1) EP3442523A4 (https=)
JP (3) JP6980694B2 (https=)
KR (2) KR102395342B1 (https=)
CN (2) CN120114438A (https=)
AU (1) AU2017248665B2 (https=)
CA (1) CA3020815A1 (https=)
IL (2) IL298314B2 (https=)
WO (1) WO2017180907A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
EP3914595A4 (en) 2019-01-22 2022-11-09 Sorrento Therapeutics, Inc. METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN
CA3188689A1 (en) * 2020-08-11 2022-02-17 Alexis G. Nahama Treating pulmonary inflammatory disease by neural ablation
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
US20100158973A1 (en) * 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
WO2012045587A1 (en) * 2010-10-06 2012-04-12 Celltrend Gmbh A new method for diagnosing hypertension as well as cardiomyopathies
MY172557A (en) * 2013-09-17 2019-12-02 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Also Published As

Publication number Publication date
EP3442523A4 (en) 2019-12-04
EP3442523A1 (en) 2019-02-20
CN109562096A (zh) 2019-04-02
JP7341203B2 (ja) 2023-09-08
JP6980694B2 (ja) 2021-12-15
IL298314B1 (en) 2024-12-01
JP2019511536A (ja) 2019-04-25
IL298314B2 (en) 2025-04-01
IL262328A (en) 2018-11-29
AU2017248665B2 (en) 2023-01-05
WO2017180907A1 (en) 2017-10-19
JP2023155365A (ja) 2023-10-20
IL262328B (en) 2022-12-01
CA3020815A1 (en) 2017-10-19
US20170296506A1 (en) 2017-10-19
US20250082605A1 (en) 2025-03-13
US20220000837A1 (en) 2022-01-06
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
KR20220062667A (ko) 2022-05-17
AU2017248665A1 (en) 2018-11-08
KR102395342B1 (ko) 2022-05-10
IL298314A (en) 2023-01-01
IL262328B2 (en) 2023-04-01
JP2022001608A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
US20250082605A1 (en) Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
Gramling-Babb et al. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience
Chierichini et al. The effect of norepinephrine versus epinephrine in irrigation fluid on the incidence of hypotensive/bradycardic events during arthroscopic rotator cuff repair with interscalene block in the sitting position
De Vries et al. Spinal cord stimulation for ischemic heart disease and peripheral vascular disease
Ishak et al. Feasibility, safety, and efficacy of subcutaneous peripheral nerve field stimulation for the treatment of refractory low back pain: a two-year single-center study
Casutt et al. Ultrasound-guided carotid sheath block for carotid endarterectomy: a case series of the spread of injectate
JP2001510794A (ja) レボブピバカインとその使用
Trentman et al. Occipital nerve stimulator placement via a retromastoid to infraclavicular approach: a technical report
Yakovlev et al. Treatment of chronic intractable atypical facial pain using peripheral subcutaneous field stimulation
Lipov of Spinal Cord and Peripheral Nerve Field Stimulation to Treat Low Back and Leg Pain
Costa et al. Microneurographic evidence of sudden sympathetic withdrawal in carotid sinus syncope; treatment with ergotamine
De Andrés et al. Use of a spinal cord stimulator for treatment of Martorell hypertensive ulcer
Royal Resiniferatoxin for permanent pain relief in cancer patients
RU2200030C2 (ru) Способ спинальной анестезии
Kočan et al. Therapeutic possibilities in patients with refractory angina pectoris: spinal cord stimulation
WO2024153981A1 (en) A medicinal product for use in administering in the treatment, control and/or prevention of pain
Sudhakaran et al. A prospective study evaluating the effectiveness of epidural volume extension with normal saline in combined spinal epidural anesthesia for lower limb orthopedic surgeries using low dose intrathecal hyperbaric bupivacaine.
Głuszek et al. Devices for the treatment of arterial hypertension
Singh Assessment of Unilateral Spinal Anaesthesia with 6 Mg of 0.5%(Hyperbaric) Bupivacaine and 90 µg of Buprenorphine Using Low Dose-Slow Injection Technique: A Prospective Study
Staudt et al. Neuromodulation for Non-urologic Chronic Pain
Yakovlev Treatment of cancer related pain using spinal cord stimulation
Gaurav Comparison of onset and duration of Blockade between equipotent doses of Ropivacaine-fentanyl and bupivacaine-Fentanyl in lower abdominal surgeries under Spinal anaesthesia–a one year hospital based Randomized clinical study
Huh Spinal cord stimulation for managing angina from coronary artery disease
Aronson Drugs that affect autonomic functions or the extrapyramidal system
Anurag Srivastava Comparison Of Onset And Duration Of Blockade And Post Operative Analgesia Of Isobaric Ropivacaine 0.75% With Fentanyl And Isobaric Ropivacaine 0.5% With Fentanyl In Female Patients Undergoing Lower Abdominal Surgeries Under Epidural Anaesthesia-A One Year Hospital Based Randomised Controlled Trial

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination